M. El-Maraghy, ChristineM. Amer, SawsanSalem, HeshamNebsen, Marianne2020-02-092020-02-092016[1] P.Baumann; International Clinical Psychopharma- cology, 11, (1996). [2] J.Menegola, M.Steppe, E.E.S.Schapoval;J.AOAC Int., 91, (2008). [3] J.Macek, P.Ptacek J.Kima; J.Chromatogr.B, 755, (2001). [4] HPLC method supplied by SEDICO company through personal communication. [5] B.Narayana, K.Veena; J.Mex.Chem.Soc., 54, (2010). [6] A.Raza; Chem.Pharm.Bull., 54, (2006). [7] I.A.Darwish, I.H.Refaat; J.AOAC Int., 89, (2006). [8] T.G.Halvorsen, S.Pedersen-Bjergaard, K.E.Rasmussen;J.Chromatogr.A, 909, (2001). [9] Z.Rong, X.Shangyou, X.Hongmei, H.Rui, X.Zhining; Chin.j.Anal.chem., 34, (2006). [10] J.J.B.Nevado, C.G.Cabanillas, M.J.V.Llerena, V.R.Robledo;J.Chromatogr.A, 1072, (2005). [11] S.R.Dhaneshwar, M.V.Mahadik; J.AOAC Int., 92, (2009). [12] R.N.Rao, A.N.Raju, R.Narsimha; J.Sep.Sci., 31, (2008). [13] M.Sharma, P.R.Jawa, R.S.Gill, G.Bansal; J.Braz.Chem.Soc., 22, (2011). [14] A.Afkhami, M.Bahram; Spectrochim Acta A Mol Biomol Spectrosc, 61, (2005). [15] A.Afkhami, M.Bahram; Talanta, 66, (2005). [16] E.DinÁ, ÷.‹st¸ndað; Il Farmaco, 58, (2003). [17] R.G.Brereton;Analyst, 122, (1997). [18] H.W.Darwish, S.A.Hassan, M.Y.Salem, B.A.El- Zeiny; SpectrochimActaAMol Biomol Spectrosc, 83, (2011). [19] ICHóInternational Conference on Harmonization, of Technical Requirementsfor registration of Phar- maceuticalsfor Human Use Topic Q2 (R1), Validation of Analytical Procedures; Text and Methodol- ogy, Geneva, Switzerland, (2005). [20] R.Kramer; Chemometric Techniques for Quantitative analysis, Marcel dekker; New York, (1998). [21] F.Navarro-Villosalade,L.V.Prez-Arrbas, M.E.Leon- Gonzalez, L.M.Polo-Diez; Anal.Chim.Acta, 313, (1995). [22] K.R.Beebe,R.J.Pell, M.B.Seashlotz;Chemometrics, APractical Guide,JohnWiley, Sons,Inc., NewYork, (1998).0974-7419https://doi.org/https://t.ly/bR7D1MSA Google ScholarSimple, accurate, sensitive and validated UV stability-indicating spectro- photometric and chemometric methods were developed for determination of Citalopram Hydrobromide (CT) in presence of its alkaline, oxidative degradation products and in its pharmaceutical preparation. Method (A) is a successive derivative ratio spectrophotometricone, which depends on the successive derivative ofratio spectra in two steps and measuring Citalopram Hydrobromide at 277nm and 293nm. Method (B) is mean centering of ratio spectra which dependson using the mean centered ratio spectra in two successive steps and measuring the mean centeredvalues of the second ratio spectra at 237nm and method (C) used two chemometric techniques ; principal component regression(PCR) and partial least-squares (PLS). The proposed methods werechecked using laboratory-prepared mixtures and were successfully applied for the analysis of pharmaceuticalformulation containing Citalopram Hydrobromide. The proposed methods were vali- dated according to the ICH guidelines. The obtained results were statisti- cally compared with those obtained froma compendial HPLC method,showing no significant difference with respect to accuracy and precision.enUniversity of Citalopram hydrobromide; Degradation; Stability-indicating; Successive derivative ratio; Mean centering of ratio spectra; ChemometricsArticlehttps://doi.org/